Budoucí P/E společnosti Ayala Pharmaceuticals

Jaká je hodnota metriky Budoucí P/E společnosti Ayala Pharmaceuticals?

Hodnota metriky Budoucí P/E společnosti Ayala Pharmaceuticals Inc. je -0.14

Jaká je definice metriky Budoucí P/E?



Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Budoucí P/E společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Ayala Pharmaceuticals

Čemu se věnuje společnost Ayala Pharmaceuticals?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Firmy s metrikou budoucí p/e podobnou společnosti Ayala Pharmaceuticals